Aglaia Oncology Funds
Aglaia Oncology Funds is a venture capital company dedicated to investing in early-stage oncology drug development companies. With extensive experience in cancer research and drug development, Aglaia focuses on selecting and nurturing breakthrough inventions with the potential to revolutionize cancer treatment. The company emphasizes impact investing, aiming to generate societal benefits alongside financial returns, and actively participates in the strategic and operational development of its portfolio companies. It manages several funds, including active and planned ones, and has invested in numerous biotech companies and products. Aglaia also prioritizes socio-economic impact measurement and adheres to SFDR disclosures, integrating sustainability and impact considerations into its investment process.
Industries
Nr. of Employees
small (1-50)
Aglaia Oncology Funds
Bilthoven, Utrecht, The Netherlands, Europe
Products
Nanoparticle-based vaccine platform with modular surface conjugation
A biodegradable polymeric nanoparticle platform that supports controlled antigen display via modular copper-free click conjugation, virus-mimicking particle sizing, and formulation options compatible with GMP-scale production and freeze-drying for reduced cold-chain dependence.
Copper-free click chemistry reagent set for conjugation
A collection of strain-promoted alkyne reagents and linkers designed for fast, versatile conjugation of small molecules and biologics to carriers, intended for research and potential translation.
Nanoparticle-based vaccine platform with modular surface conjugation
A biodegradable polymeric nanoparticle platform that supports controlled antigen display via modular copper-free click conjugation, virus-mimicking particle sizing, and formulation options compatible with GMP-scale production and freeze-drying for reduced cold-chain dependence.
Copper-free click chemistry reagent set for conjugation
A collection of strain-promoted alkyne reagents and linkers designed for fast, versatile conjugation of small molecules and biologics to carriers, intended for research and potential translation.
Services
Venture capital investment and portfolio management
Provision of fund capital, selection of early-stage oncology investments, active portfolio management and follow-on financing.
Strategic R&D planning and translational support
Design and oversight of R&D plans from early screening and animal feasibility studies through clinical development to de-risk programs for clinical entry.
Impact measurement and reporting implementation
Implementation and use of a web-based indicator framework to measure socio-economic, clinical and financial impact of life sciences investments.
Investment due diligence including ESG and IP assessment
Pre-investment evaluation covering technology potential, patentability, modality fit and sustainability/ESG risk assessment as part of investment decision-making.
Vaccine development and CDMO-style translational support
Access to translational vaccinology expertise and manufacturing infrastructure to support preclinical evaluation and progression of vaccine candidates into early clinical studies.
Mass spectrometry imaging and biodistribution analytics
Analytical services using high-spatial-resolution mass spectrometry imaging to assess intratumour localisation and drug-release behaviour of nanoparticle therapeutics.
Venture capital investment and portfolio management
Provision of fund capital, selection of early-stage oncology investments, active portfolio management and follow-on financing.
Strategic R&D planning and translational support
Design and oversight of R&D plans from early screening and animal feasibility studies through clinical development to de-risk programs for clinical entry.
Impact measurement and reporting implementation
Implementation and use of a web-based indicator framework to measure socio-economic, clinical and financial impact of life sciences investments.
Investment due diligence including ESG and IP assessment
Pre-investment evaluation covering technology potential, patentability, modality fit and sustainability/ESG risk assessment as part of investment decision-making.
Vaccine development and CDMO-style translational support
Access to translational vaccinology expertise and manufacturing infrastructure to support preclinical evaluation and progression of vaccine candidates into early clinical studies.
Mass spectrometry imaging and biodistribution analytics
Analytical services using high-spatial-resolution mass spectrometry imaging to assess intratumour localisation and drug-release behaviour of nanoparticle therapeutics.
Expertise Areas
- Early-stage oncology drug development
- Translational research and preclinical validation
- Clinical development strategy and trial enabling
- Venture creation and portfolio management
Key Technologies
- Organ-on-chip / microfluidic human tissue models
- Polymeric nanoparticle nanomedicines
- Bioconjugation chemistry for ADCs and vaccine conjugates
- Synthetic long peptide vaccine platforms